Daniel G. Welch
Chairman of the Board

Daniel Welch has served as a member of the Ultragenyx board since April 2015. He serves as the chairperson of public biotechnology companies Structure Therapeutics (previously known as ShouTi) and Prothena Corporation plc. Between January 2015 and January 2018, Daniel was an Executive Partner at Sofinnova Ventures, a venture capital firm. Prior to Sofinnova, he served as Chairman, Chief Executive Officer, and President of InterMune, Inc., a biotechnology company, from May 2008 to October 2014 and served as President and Chief Executive Officer of InterMune and a member of its board of directors from September 2003 to May 2008. From August 2002 to January 2003, Daniel served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., a pharmaceutical company. From October 2000 to June 2002, he served as President of the pharmaceutical division of Elan Corporation, plc. Daniel previously served as chairman of the board of directors of Nuvation Bio from July 2020 to September 2024 and as a director on the boards of directors of Intercept Pharmaceuticals, Inc from November 2015 to June 2021 and Seagan Inc. from July 2007 to December 2023. Daniel holds a an M.B.A. from the University of North Carolina and a B.S. from the University of Miami.